Mythic Therapeutics Appoints George Eliades, Ph.D., as President and Chief Executive Officer
28 March 2024 - 10:00PM
Business Wire
Mythic Therapeutics, a clinical-stage biotechnology company
committed to the development of next-generation antibody-drug
conjugate (ADC) therapies for the treatment of a wide range of
cancers, announced that George Eliades, Ph.D., has joined the
company as President and Chief Executive Officer (CEO).
“I am delighted to welcome George to the Mythic team,” said
Brian Fiske, Ph.D., Chief Scientific Officer and Co-Founder at
Mythic Therapeutics. “George’s extensive experience in corporate
strategy, business development and launching innovative medicines
in oncology, coupled with his vision and proven leadership, will be
invaluable as we move into our next phase of growth and innovation
with our clinical and preclinical ADC candidates.”
Dr. Eliades joins Mythic from Jazz Pharmaceuticals, where he was
a member of the executive team, serving as the Senior Vice
President of Corporate Development and Chief Transformation
Officer. In his 4 years at Jazz Pharmaceuticals, he led the $7.2B
acquisition and integration of GW Pharmaceuticals, the acquisition
of development and commercial rights for JZP898 and JZP441, two
early-stage clinical programs for treating solid tumors and sleep
disorders, and the licensing agreement for zanidatamab, an
investigational HER2-targeted bispecific antibody. Prior to that,
Dr. Eliades spent over 20 years at Bain & Company and Monitor
Group, advising biotech clients in corporate strategy, M&A,
growth and digital-driven transformations.
Dr. Eliades stated, “I’m incredibly excited to join Mythic and
work toward improving outcomes for more cancer patients through our
pipeline of innovative ADCs. I look forward to working with the
leadership team and employees to accelerate clinical development of
the Company’s lead therapeutic candidate, MYTX-011, and continue
expanding the application of our platform to develop impactful
therapies for patients.”
“This team has made significant strides in developing its
pipeline, with a unique focus on the antibody component of the
ADC,” said Bryan Roberts, Partner of Venrock and a member of
Mythic’s Board of Directors. “Dr. Eliades joins at a critical time
where his leadership and wealth of industry experience will be
instrumental in building an enduring multi-product oncology company
as it continues to expand its ADC-focused pipeline and drive toward
transformative outcomes for cancer patients.”
About Mythic Therapeutics
Mythic Therapeutics is a product-platform company developing a
pipeline of antibody-drug conjugates (ADCs) designed to exhibit
unparalleled therapeutic index and efficacy. The Company’s
FateControl™ technology aims to enhance ADC uptake in targeted
tissues by manipulating the fate of the ADC within the cell,
thereby expanding the diseases and patient profiles that could be
treated with Mythic’s ADCs. The company’s major investors include
Venrock, Viking Global Investors, and First Round Capital.
For more information, visit: www.mythictx.com and follow on
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240328009665/en/
Media Contact: Media@mythictx.com